XML 22 R10.htm IDEA: XBRL DOCUMENT v3.20.2
EARNINGS PER SHARE
 9 Months Ended
Sep. 30, 2020
Earnings Per Share, Basic and Diluted [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS PER SHARE
    The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Amounts attributable to Quest Diagnostics’ common stockholders:    
Income from continuing operations$568 $215 $852 $585 
Income from discontinued operations, net of taxes— — — 20 
Net income attributable to Quest Diagnostics’ common stockholders$568 $215 $852 $605 
Income from continuing operations$568 $215 $852 $585 
Less: Earnings allocated to participating securities2 1 3 2 
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$566 $214 $849 $583 
Weighted average common shares outstanding – basic135 135 134 135 
Effect of dilutive securities:    
Stock options and performance share units2 2 2 1 
Weighted average common shares outstanding – diluted137 137 136 136 
Earnings per share attributable to Quest Diagnostics’ common stockholders - basic:
    
Income from continuing operations$4.20 $1.59 $6.33 $4.33 
Income from discontinued operations— — — 0.15 
Net income$4.20 $1.59 $6.33 $4.48 
Earnings per share attributable to Quest Diagnostics’ common stockholders – diluted:
    
Income from continuing operations$4.14 $1.56 $6.25 $4.27 
Income from discontinued operations— — — 0.15 
Net income$4.14 $1.56 $6.25 $4.42 
    
    The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Stock options1 2 1 3 

    The sum of basic and diluted earnings per share attributable to Quest Diagnostics' common stockholders for the first three quarters of 2020 did not equal the totals for the nine months ended September 30, 2020 due to quarterly fluctuations in the Company's earnings and weighted average common shares outstanding throughout the period as a result of the impact of COVID-19 (see Note 2 for further details) and the temporary cessation of repurchases under the Company's share repurchase program (see Note 10 for further details).